ENGLISH CV |
| Quick click! | Identity | 1998- | 1991-1997 | 1985-1991 | 1981-1985 | 1978 - 1981 | Miscellaneous | Back |
|---|
|
Jean H . H U B E R |
C.V. in English (July 2007) |
|---|---|
| ID | French, born February 10.,
1952 7, boulevard Flandrin, 75116 Paris, FRANCE. Phone: + 33 6 31 67 07 76 Work experience : 29 years in the Pharmaceutical Industry 11 years, Business / Territory Management / Licensing / Sales 9 years, Product Marketing / Customer Relationship Management / New channels 9 years, Strategic Planning / Management Control / Finance / Merger & Acquisition / Economics |
| 1998- : | CONSULTANT (Arcos) - Consultancy on 3 main (equal) items : health economics / pricing, Marketing, Communication (CRM, Internet) / Business Development. Created the Pharmaclient Internet Golden Award (2004, 2006) and E-Pharmaclient News (monthly, 5 years). Consultancy concerning the healthcare plans in France (vs. rest of Europe) and health economics. Consultancy for communication agencies: "launch-repositioning strategies" for tender offers. Developed first a freelance activity for third parties more deeply on CRM and (e)C.R.M., on Internet issues, on anticancer, cardiovascular, biotech and C.N.S. drugs, old age patients (dependency), on distribution and communication channels, on MD's networks, on patients' associations (EHR), on pricing and many short term issues (business intelligence and business development). Typical clients: Pharma industry, subcontractors, analysts, consultants. |
| 1991-1997 : |
BIOCODEX (40 Million € in 1991), European business manager (Country management) - Managed a profit centre of 11 Million €, the drug Ultralevure (ethical/OTC) accounting for 95%. Management of the single subsidiary in Belgium (17 people), administration and medico-marketing co-ordination of licensees: S.B. in Italy, Astra in Scandinavia, B.M.S.-Upsa in Spain, Akzo in Germany, Merck in Portugal. Successfully managed delisting threats, generic attacks, pricing moves, organisational restructuring and switches to OTC. A hands-on operational duty. |
| 1985-1991 : |
RHONE POULENC HEALTH DIVISION, Group planning manager (Pharmacy sector), now
SANOFI - Reported to the Deputy General Manager in charge of Economy-Finance-Administration (about 2 Billion € in 1989, 75% of the Health Division): a staff position within headquarters. Qualified in all strategic pharma-issues, interfacing with members of the executive team and their direct associates. - Analysed annually 3 year business plans, on behalf of the operational area managers, of each of the 20 largest subsidiaries: identified stakes and action plans by country, for developing the objectives per area and for the General Management (acquisition and investment issues). - Led multidisciplinary teams to build the strategic plan which has culminated in the Rorer deal (product-market portfolio with 10 year projections, target profits, relative gaps fulfilment) and took a major part in strategic projects (Development Expenses, Generics, International Transfer Pricing, New Product Pricing, Information Technology, Industrial Productivity...). - Elaborated or diagnosed dozens of acquisition ventures of which 15 have succeeded, before Rorer, weighting 550 Million € of additional turnover in 4 years. Directly acted in the negotiations of 4 of them‚ in North America and Europe (stake: 300 Million €). Since its very beginning (September 89), a key member of the restricted team for the deal with Rorer to aggregate one among the then 10 largest groups world-wide (3.2 Billion € pro forma in 1990). Notably in charge of financial, planning and legal aspects of the leverage before the public offering, then of the first steps of the actual merger of the major European subsidiaries of both companies. - Designed, with the support of the appropriate departments, numerous selective surveys‚ in various fields and advised the executive team of the issues and recommendations. Fields addressed: audits, internal diagnostics and of competition (marketing and finance), investments in production and R&D, potential diversification, O.T.C., L.B.O. financing, information to financial analysts, government policy and health economics, restructuring of a wide product portfolio. |
| 1981-1985 : |
I.C.I. - PHARMA FRANCE (80 Million € in 1985), Product Manager Tenormin First product of the subsidiary (40% of turnover) and of the I.C.I. group (now AstraZeneca). Achieved the number 1 position on the French market. Yearly growth of 20%. - Conceptualised the promotional campaigns for 2 sales teams (three times a year). - Managed a 4 people's team with 2 cardiovascular MD's. - Controlled a direct promotional budget of 1 Million € p.a. |
| 1978-1981 : | ELI LILLY FRANCE (40 Million € in 1981), Medical Rep. (18 months; challenge winner). P.R. with opinion leaders and GP's, Market Research (Antibiotics, Anticancer), Launch of Nalgesic. |
| MISCELLANEOUS |
Education : 1977 - 1978 : M . B . A . in INSEAD, Fontainebleau. 1973 - 1978 : Ph. D. (Biological Science), Nancy University. 1973 - 1976 : Engineer of E.N.S. Physique - Chimie, Bordeaux. Languages : Outside interests : Sportsman. Music lover. |
Actualisation / Updating: Aug 01 2007
| Pause...Citation, Humour, Quizz | Réponse |
|
"Mi-figue mi-raisin" est une expression qui dénote aujourd'hui l'ambiguïté. Un sens un peu détourné, car il s'agit d'une arnaque commerciale. En savez-vous davantage? |
QUIZ6 |
Pharmaclient est le site-conseil de la Valorisation Client
en Pharma...
Pour toute Mission, Inscription à la Pharmagalerie, ou Question:
CONTACT
Pour retourner à la page d'accueil: BIENVENUE !
Copyright J.H. Huber, Pharmaclient 2001-2006.